Literature DB >> 8660076

Calprotectin as a marker of inflammation in cystic fibrosis.

B E Golden1, P A Clohessy, G Russell, M K Fagerhol.   

Abstract

Calprotectin is an abundant neutrophil cytosolic protein released during neutrophil activation or death. The use of plasma calprotectin concentration as a marker of pulmonary inflammation was tested in 31 children with cystic fibrosis, none of whom was acutely unwell or pyrexic. Twenty three were receiving antibiotics, 21 had positive sputum cultures, but none of the traditional tests clearly diagnosed ongoing infection. Plasma calprotectin was significantly higher in the cystic fibrosis group than in matched controls. Sixteen children with cystic fibrosis had values above the control range (320-1570 micrograms/l). Their chest radiograph Northern score, an index of accumulated pulmonary involvement, and their plasma copper, an index of acute phase response, both correlated with plasma calprotectin. Plasma gamma-glutamyltransferase also correlated weakly with plasma calprotectin: thus, hepatic pathology may be a confounding variable. However, the data still suggested that plasma calprotectin is a better index of inflammation than the traditional indices in general use.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8660076      PMCID: PMC1511506          DOI: 10.1136/adc.74.2.136

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN: 0003-9888            Impact factor:   3.791


  17 in total

1.  Assessment of the neutrophil dominating protein calprotectin in feces. A methodologic study.

Authors:  A G Røseth; M K Fagerhol; E Aadland; H Schjønsby
Journal:  Scand J Gastroenterol       Date:  1992-09       Impact factor: 2.423

2.  Plasma levels of the calcium-binding L1 leukocyte protein: standardization of blood collection and evaluation of reference intervals in healthy controls.

Authors:  I Dale
Journal:  Scand J Clin Lab Invest       Date:  1990-12       Impact factor: 1.713

3.  Changes in total, nondiffusible, and diffusible plasma zinc and copper during infancy.

Authors:  R I Henkin; J D Schulman; C B Schulman; D A Bronzert
Journal:  J Pediatr       Date:  1973-05       Impact factor: 4.406

4.  Demonstration of serum protein differences in cystic fibrosis by isoelectric focusing in thin-layer polyacrylamide gels.

Authors:  G B Wilson; T L Jahn; J R Fonseca
Journal:  Clin Chim Acta       Date:  1973-11-23       Impact factor: 3.786

5.  Plasma levels of the leucocyte L1 protein in febrile conditions: relation to aetiology, number of leucocytes in blood, blood sedimentation reaction and C-reactive protein.

Authors:  J Sander; M K Fagerhol; J S Bakken; I Dale
Journal:  Scand J Clin Lab Invest       Date:  1984-06       Impact factor: 1.713

6.  Identification of 'cystic fibrosis protein' as a complex of two calcium-binding proteins present in human cells of myeloid origin.

Authors:  C Barthe; C Figarella; J Carrère; O Guy-Crotte
Journal:  Biochim Biophys Acta       Date:  1991-02-22

7.  Host inflammatory responses to first isolation of Pseudomonas aeruginosa from sputum in cystic fibrosis.

Authors:  J S Elborn; S M Cordon; D J Shale
Journal:  Pediatr Pulmonol       Date:  1993-05

8.  Relationship of neutrophil cytoplasmic protein (L1) to acute and chronic lung disease.

Authors:  R A Stockley; I Dale; S L Hill; M K Fagerhol
Journal:  Scand J Clin Lab Invest       Date:  1984-11       Impact factor: 1.713

9.  The chest radiograph in cystic fibrosis: a new scoring system compared with the Chrispin-Norman and Brasfield scores.

Authors:  S P Conway; M N Pond; I Bowler; D L Smith; E J Simmonds; D N Joanes; G Hambleton; E J Hiller; D E Stableforth; P Weller
Journal:  Thorax       Date:  1994-09       Impact factor: 9.139

10.  Modification of some markers of inflammation during treatment for acute respiratory exacerbation in cystic fibrosis.

Authors:  E A Valletta; A Rigo; L Bonazzi; L Zanolla; G Mastella
Journal:  Acta Paediatr       Date:  1992-03       Impact factor: 2.299

View more
  24 in total

Review 1.  Multifarious diagnostic possibilities of the S100 protein family: predominantly in pediatrics and neonatology.

Authors:  Anna Medkova; Josef Srovnal; Jarmila Potomkova; Jana Volejnikova; Vladimir Mihal
Journal:  World J Pediatr       Date:  2018-06-01       Impact factor: 2.764

Review 2.  Functional and clinical aspects of the myelomonocyte protein calprotectin.

Authors:  B Johne; M K Fagerhol; T Lyberg; H Prydz; P Brandtzaeg; C F Naess-Andresen; I Dale
Journal:  Mol Pathol       Date:  1997-06

3.  Plasma calprotectin levels in patients suffering from acute pancreatitis.

Authors:  Antonio Carroccio; Pasquale Rocco; Pier Giorgio Rabitti; Lidia Di Prima; Giovanni Battista Forte; Angelo B Cefalù; Franco Pisello; Girolamo Geraci; Generoso Uomo
Journal:  Dig Dis Sci       Date:  2006-10       Impact factor: 3.199

4.  The C-terminus of murine S100A9 protein inhibits hyperalgesia induced by the agonist peptide of protease-activated receptor 2 (PAR2).

Authors:  C S Dale; N Cenac; L R G Britto; M A Juliano; L Juliano; N Vergnolle; R Giorgi
Journal:  Br J Pharmacol       Date:  2006-09-11       Impact factor: 8.739

5.  Calprotectin expression inhibits bacterial binding to mucosal epithelial cells.

Authors:  K Nisapakultorn; K F Ross; M C Herzberg
Journal:  Infect Immun       Date:  2001-06       Impact factor: 3.441

6.  S100A8 and S100A9 inhibit neutrophil oxidative metabolism in-vitro: involvement of adenosine metabolites.

Authors:  Herve Y Sroussi; Yu Lu; Qin L Zhang; Dana Villines; Phillip T Marucha
Journal:  Free Radic Res       Date:  2010-04

7.  Expression of S100A12 (EN-RAGE) in cystic fibrosis.

Authors:  D Foell; S Seeliger; T Vogl; H-G Koch; H Maschek; E Harms; C Sorg; J Roth
Journal:  Thorax       Date:  2003-07       Impact factor: 9.139

8.  Contributions of the S100A9 C-terminal tail to high-affinity Mn(II) chelation by the host-defense protein human calprotectin.

Authors:  Megan Brunjes Brophy; Toshiki G Nakashige; Aleth Gaillard; Elizabeth M Nolan
Journal:  J Am Chem Soc       Date:  2013-11-18       Impact factor: 15.419

Review 9.  Calprotectin: Clinical Applications in Pediatrics.

Authors:  Oscar R Herrera; Michael L Christensen; Richard A Helms
Journal:  J Pediatr Pharmacol Ther       Date:  2016 Jul-Aug

Review 10.  The role of calprotectin in pediatric disease.

Authors:  George Vaos; Ioannis D Kostakis; Nick Zavras; Athanasios Chatzemichael
Journal:  Biomed Res Int       Date:  2013-09-23       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.